Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

What happened to Sangamo yesterday?

September 6, 2018 0

The disease, mucopolysaccharidosis (MPS) type II, also known as the horrible Hunter syndrome is a killer …

Outperforming, favorite, and undervalued biotech firms

September 3, 2018 0

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid …

RegenxBio has good news

August 30, 2018 0

We reiterate that undeniably outstanding news about gene therapy is taking time to penetrate investors’ ears. …

Ionis, the FDA and the exaggerated selloff of the firm’s stock

August 30, 2018 0

A complete response letter (CRL) sent by The Division of Metabolism and Endocrinology Products of the …

PTC Therapeutics now with a wealthier pipeline

August 28, 2018 0

Before we sell PTC Therapeutics (PTCT), after the stock had reached and surpassed our latest and …

About Portola

August 27, 2018 0

Portola (PTLA) has two important approved breakthrough products and an investigational product having promising results on …

When all the prophets are taken by surprise

August 24, 2018 0

When the Goal is Reaching into the Future, Pessimists Have No Place on the Ship The …

Why Celyad’s stock gained $2.30 today

August 23, 2018 0

Celyad (CYAD) is an immuno-oncology firm, which created CAR T CELL treatments for cancers, including solid …

Starting the gene therapy chapter in the book of the biotech revolution

August 22, 2018 0

WE ARE LIVING AN HISTORIC BIOLOGICAL REVOLUTION. Unfortunately, the undeniably outstanding news has not yet penetrated …

Vertex has good news from Australia. Why selling solid firms stocks.

August 21, 2018 0

Vertex Pharmaceuticals (VRTX) announced that the Pharmaceutical Benefits Advisory Committee’s (PBAC) in Australia recommendation the listing …

Regeneron: Two good news and a rebound on the road

August 17, 2018 0

The FDA Approves Regeneron’s Product EyLea® (aflibercept) sBLA in Wet Age-Related Macular Degeneration Regeneron (REGN) has …

Aerie’s successful new confirmatory study for Rhopressa® was a necessity

August 15, 2018 0

Aerie Pharmaceuticals (AERI) announced results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect …

Bombarding future treatment approaches

August 15, 2018 0

The Week in Review #27 PRIORITY TOPICS: CRISPR GENE EDITING, GENETIC ENGINEERING & ANTISENSE TECHNOLOGY The choice of these …

Regeneron’s and Bluebird Bio’s collaboration is meant to create advanced immune cell therapy

August 9, 2018 0

Regeneron Pharmaceuticals (REGN) and bluebird bio, Inc. (BLUE) announced a collaboration to apply their respective technology platforms to the …

Why Portola couldn’t flex its muscles or use them yet

August 9, 2018 0

All the buying and selling of Portola (PTLA) will not make any sense to us until the …

Spark Therapeutics: A usual reaction to SPK-8011 results should have been a celebration

August 8, 2018 0

When an investigational gene therapy gets excellent results, the usual reaction towards the developing firm is …

Exelixis: Why Q2 results are more than impressive

August 2, 2018 0

Exciting are the Q2 2018 reported results by Exelixis’ (EXEL) including the firm’s revenues and earnings, …

Victims of fear and misunderstanding

August 1, 2018 0

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical …

A new European approval for Bristol-Myers’ immunotherapy opdivo. The future is starting now

July 31, 2018 0

The Future is Starting Now Recognizing that the future has already started now is important as …

The EU CHMP Recommends Approving Alnylam’s RNAi Therapeutic, ONPATTRO™

July 27, 2018 0

The Committee for Medicinal Products for Human Use (CHMP) announced a Positive Opinion recommending marketing authorization of Alnylam’s …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd